Related Experiment Video
Updated: May 26, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
[Castration-resistant prostate cancer: where are we going?]
A Alcaraz1, R Medina, P Maroto
1Servicio de Urología, IDIBAPS, Hospital Clínic de Barcelona, Barcelona, España. aalcaraz@clinic.ub.es
Actas Urologicas Espanolas
|December 23, 2011
Summary
New treatments offer hope for advanced prostate cancer. Novel drugs like cabazitaxel and abiraterone improve survival for castration-resistant prostate cancer patients after docetaxel failure.
Area of Science:
- Oncology
- Urology
Context:
- Metastatic prostate cancer often progresses to castration-resistant prostate cancer (CRPC) despite hormonal therapy.
- Androgen suppression resistance necessitates alternative treatment strategies.
Purpose:
- To review the current landscape of CRPC treatment.
- To highlight the impact of emerging therapies on CRPC management.
Summary:
- Docetaxel chemotherapy marked a significant advancement in CRPC, improving survival compared to older regimens.
- Current first-line treatment involves docetaxel and prednisone; however, treatment options after progression remain limited.
- Novel agents are emerging, offering new therapeutic avenues for advanced CRPC.
Impact:
- The introduction of new drugs has significantly expanded treatment options for CRPC.
- Cabazitaxel and abiraterone demonstrate efficacy as second-line treatments, improving survival and reducing mortality risk in CRPC patients post-docetaxel progression.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...